

C/K 1394365

For Internal Use Only
Sec File No. 91-016387

Submit 1 Original
and 9 copies

OMB APPROVAL
OMB Number: 3235-0504
Expires July 31, 2004
Estimated average burden
hours per response: 2.00

SECURITIES AND EXCHANGE COMMISSION
RECEIVED

MAY 28 2007

DIVISION OF MARKET REGULATION

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDED FORM 19b-4(e).



07053527

Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

- 1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:
International Securities Exchange, LLC
- 2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):
SPDR Select Sector
- 3. Class of New Derivative Securities Product:
Investment Company Unit
- 4. Name of Underlying Instrument:
S&P Biotech Index
- 5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-based:
The index referred to in Item 4 above is narrow-based
- 6. Ticker Symbol(s) of New Derivative Securities Product:
XBI
- 7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:
New York Stock Exchange, Nasdaq Global Market and American Stock Exchange
- 8. Settlement Methodology of New Derivative Securities Product:
T+3, Physical Settlement
- 9. Position Limits of New Derivative Securities Product (if applicable):
Not Applicable

PROCESSED

JUL 23 2007

**THOMSON
FINANCIAL**

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form: **Michael J. Simon**

Title: **General Counsel and Secretary**

Telephone Number: **212 897-0230**

Manual Signature of Official Responsible for Form:

Date: **May 7, 2007**

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	MAY - 8

SECURITIES AND EXCHANGE COMMISSION
RECEIVED

MAY 8 2007

DIVISION OF MARKET REGULATION



INTERNATIONAL SECURITIES EXCHANGE.

60 Broad Street New York, NY 10004
TEL: 212 943-2400
FAX: 212 425-4926
www.iseoptions.com

May 7, 2007

By Facsimile and Overnight Courier

Gail S. Jackson
Paralegal Specialist
US Securities and Exchange Commission
Division of Market Regulation
100 F Street, NE – Room 6628
Washington, DC 20549

Re: Form 19b-4(e)

Dear Ms. Jackson:

The International Securities Exchange, LLC hereby files Form 19b-4(e), with respect to the following Investment Company Units: S&P Biotech Index, Dow Jones U.S. Industrial Sector Index, D.J. Wilshire Small Cap Index, S&P 1500 Index, Vanguard Information Technology Index, Vanguard Financials Index, and Vanguard Consumer Staples Index. These securities are listed for trading pursuant to ISE Rule 2123.

Sincerely,

Michael J. Simon
General Counsel and Secretary

Attachment

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	MAY - 8 2007

END